Mir Hashim - 29 Jul 2021 Form 3/A - Amendment Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Role
Chief Scientific Officer
Signature
/s/ Josh Seidenfeld, Attorney-in-Fact for Mir Hashim
Issuer symbol
RANI
Transactions as of
29 Jul 2021
Net transactions value
$0
Form type
3/A - Amendment
Filing time
02 Aug 2021, 20:09:17 UTC
Date Of Original Report
29 Jul 2021
Next filing
13 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding RANI Class B Common Stock 171,985 29 Jul 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RANI Class A Common LLC Units 29 Jul 2021 Class A Common Stock 545,624 Direct F1, F2
holding RANI Stock Option (Right to Buy) 29 Jul 2021 Class A Common Stock 211,313 $9.45 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correctly reflect the shares held.
F2 Represents Common LLC Units of Rani Therapeutics, LLC, a direct subsidiary of the Issuer. The Common LLC Units are redeemable at the election of the Reporting Person at any time for newly-issued Class A Common Stock of the Issuer ("Class A Shares") on a one-for-one basis or, if mutually agreed with the Issuer, a cash payment equal to the volume weighted average market price of one Class A Share for each Common LLC Unit redeemed (subject to customary adjustments, including for stock splits, stock dividends and reclassifications). However, the Issuer may elect to effect a direct exchange of such Class A Shares (or such cash, if mutually agreed) for such Common LLC Units.
F3 The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.
F4 This amendment is being filed to correctly reflect the exercise price of the Stock Option.